Sunday, November 1, 2026

Catalyst Pharmaceuticals Stock Went Up By Over 3% On Tuesday

ViaNews Editorial Team

December 8, 2020

Catalyst Pharmaceuticals Stock Went Up By Over 3% On Tuesday

Shares of Catalyst Pharmaceuticals rose 3.5% to $3.55 at 16:08 EST on Tuesday, after two sequential sessions in a row of losses. The Nasdaq Stock Market is jumping 0.45% to $12,576.50, after three sequential sessions in a row of gains, on what up until now seems, a somewhat positive trend trading session today.

Catalyst Pharmaceuticals's last close was $3.43, 48.73% under its 52-week high of $5.28.

Catalyst Pharmaceuticals's Sales

Catalyst Pharmaceuticals's sales growth is 11.6% for the present quarter and 4.6% for the next. The company's growth estimates for the ongoing quarter is 25% and a drop 10% for the next.

Catalyst Pharmaceuticals's Revenue

Year-on-year quarterly revenue growth declined by 5.1%, now sitting on 118.18M for the twelve trailing months.

Catalyst Pharmaceuticals's Stock Top and Bottom Yearly Value

Catalyst Pharmaceuticals's stock is valued at $3.55 at 16:08 EST, way under its 52-week high of $5.28 and way above its 52-week low of $2.55.

Catalyst Pharmaceuticals's Moving Average

Catalyst Pharmaceuticals's value is higher than its 50-day moving average of $3.32 and under its 200-day moving average of $3.81.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,532 source documents archived
Query this data → isubstrate.com